{
    "relation": [
        [
            "",
            "Number of Participants [units: participants]",
            "Age [1] [units: Years] Mean (Full Range)",
            "Gender [units: Participants]",
            "Female",
            "Male",
            "Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment [2] [units: Participants]",
            "0",
            "1",
            "KRAS mutation [3] [units: Participants]",
            "No",
            "Yes",
            "Unknown"
        ],
        [
            "Regorafenib (Stivarga, BAY73-4506)+BSC",
            "505",
            "60.7 (22 to 82)",
            "",
            "194",
            "311",
            "",
            "265",
            "240",
            "",
            "205",
            "273",
            "27"
        ],
        [
            "Placebo+BSC",
            "255",
            "60.1 (25 to 85)",
            "",
            "102",
            "153",
            "",
            "146",
            "109",
            "",
            "94",
            "157",
            "4"
        ],
        [
            "Total",
            "760",
            "60.5 (22 to 85)",
            "",
            "296",
            "464",
            "",
            "411",
            "349",
            "",
            "299",
            "430",
            "31"
        ]
    ],
    "pageTitle": "Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01103323?sect=X89015&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 9,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042991076.30/warc/CC-MAIN-20150728002311-00191-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 855057194,
    "recordOffset": 855041257,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Without/Before Drug Switch Participant Flow for 2 periods Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC). Period 1 is placebo and placebo-regorafenib with placebo period only before unblinding. Period 2 is placebo-regorafenib with regorafenib period only. Placebo+BSC Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus best supportive care (BSC). Regorafenib (Stivarga, BAY73-4506)+BSC Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details",
    "textAfterTable": "\u00a0 1 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 [1] Participants in the placebo+BSC group switched to Regorafenib treatment after unblinding. \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting Groups \u00a0 Description Regorafenib (Stivarga, BAY73-4506)+BSC Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every",
    "hasKeyColumn": true,
    "keyColumnIndex": 1,
    "headerRowIndex": 0
}